Alan L Ho Selected Research

Platinum

1/2023	Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
1/2020	A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
12/2017	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
4/2015	Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
5/2013	A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan L Ho Research Topics

Disease

48	Neoplasms (Cancer) 01/2024 - 04/2009
15	Thyroid Neoplasms (Thyroid Cancer) 01/2023 - 01/2011
11	Squamous Cell Carcinoma of Head and Neck 01/2024 - 11/2013
10	Carcinoma (Carcinomatosis) 01/2024 - 09/2016
9	Salivary Gland Neoplasms (Salivary Gland Cancer) 12/2023 - 02/2017
6	Adenoid Cystic Carcinoma (Cylindroma) 12/2023 - 08/2011
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2023 - 05/2013
4	Disease Progression 06/2022 - 06/2014
3	Anemia 01/2022 - 08/2017
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2023 - 01/2014
2	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2021
2	Oropharyngeal Neoplasms 11/2021 - 01/2021
2	Papillary Thyroid Cancer 01/2021 - 01/2021
2	Stomatitis 01/2020 - 11/2017
2	Lung Neoplasms (Lung Cancer) 01/2020 - 08/2011
2	Anaplastic Thyroid Carcinoma 01/2018 - 12/2011
2	Fatigue 11/2017 - 05/2013
2	Hyperglycemia 11/2017 - 05/2013
2	Uveal melanoma 05/2013 - 01/2012
2	Melanoma (Melanoma, Malignant) 04/2013 - 01/2012
2	Sarcoma (Soft Tissue Sarcoma) 04/2013 - 09/2012
2	Polyploidy 02/2012 - 04/2009
1	Basal Cell Carcinoma (Rodent Ulcer) 04/2024
1	Epistaxis (Nosebleed) 11/2023
1	Dermatitis 10/2022
1	Infections 08/2020

Drug/Important Bio-Agent (IBA)

8	IodineIBA 01/2023 - 02/2013
7	tipifarnib (R115777)IBA 01/2024 - 01/2018
5	PlatinumIBA 01/2023 - 05/2013
5	Phosphotransferases (Kinase)IBA 05/2022 - 01/2011
4	Farnesyltranstransferase (Farnesyltransferase)IBA 01/2024 - 09/2022
4	Immune Checkpoint InhibitorsIBA 10/2023 - 01/2019
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2017 - 01/2012
3	AlpelisibIBA 01/2024 - 01/2020
3	RNA (Ribonucleic Acid)IBA 12/2023 - 09/2016
3	Biomarkers (Surrogate Marker)IBA 10/2023 - 01/2019
3	Androgen Receptors (Androgen Receptor)IBA 12/2022 - 02/2017
3	AZD 6244IBA 10/2022 - 01/2012
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2013
3	VemurafenibIBA 01/2022 - 01/2019
3	Mitogen-Activated Protein KinasesIBA 01/2022 - 01/2012
3	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 05/2013
3	taxaneIBA 12/2017 - 05/2013
3	Everolimus FDA Link 11/2013 - 09/2012
3	TOR Serine-Threonine KinasesIBA 11/2013 - 01/2012
2	Drug CombinationsIBA 01/2024 - 09/2012
2	Tyrosine Kinase InhibitorsIBA 11/2023 - 01/2019
2	larotrectinibIBA 06/2022 - 05/2022
2	Thyroglobulin FDA Link 06/2022 - 01/2019
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 01/2020
2	Eukaryotic Initiation Factor-4EIBA 01/2022 - 11/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 02/2017
2	Cetuximab (Erbitux)FDA Link 01/2020 - 01/2014
2	5'-N-methylcarboxamideadenosineIBA 01/2020 - 10/2017
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2017 - 04/2015
2	NVP-BKM120IBA 12/2017 - 04/2015
2	Carboplatin (JM8)FDA LinkGeneric 12/2017 - 04/2015
2	temsirolimus FDA Link 11/2017 - 04/2013
2	Mechanistic Target of Rapamycin Complex 1IBA 11/2013 - 09/2012
1	HhAntag691IBA 04/2024
1	IpilimumabIBA 12/2023
1	NivolumabIBA 12/2023
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2023
1	apatinibIBA 11/2023
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 11/2023
1	MK 2206IBA 11/2023
1	pembrolizumabIBA 01/2023
1	B7-H1 AntigenIBA 01/2023
1	tyramine-deoxysorbitolIBA 01/2023
1	ErbB Receptors (EGF Receptor)IBA 12/2022
1	enzalutamideIBA 12/2022
1	TropomyosinIBA 05/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Ribavirin (Virazole)FDA LinkGeneric 01/2022
1	Thyrotropin Alfa FDA LinkGeneric 01/2022
1	Sucrose (Saccharose)IBA 01/2022
1	Iodine-124IBA 01/2022
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	ChromatinIBA 01/2021
1	LigandsIBA 01/2021
1	Activins (Activin)IBA 01/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 08/2020
1	Ado-Trastuzumab EmtansineIBA 01/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	trastuzumab deruxtecanIBA 01/2020
1	Radiation-Sensitizing AgentsIBA 01/2020
1	Cytotoxins (Cytolysins)IBA 01/2020
1	lenvatinibIBA 01/2019
1	AntigensIBA 01/2019
1	afliberceptIBA 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019

Therapy/Procedure

26	Therapeutics 01/2024 - 08/2011
11	Drug Therapy (Chemotherapy) 01/2024 - 08/2011
10	Radiotherapy 04/2024 - 12/2011
5	Immunotherapy 01/2023 - 01/2019
2	Proton Therapy 01/2023 - 11/2022
2	Drug Tapering 01/2022 - 01/2020
1	Chemoradiotherapy 01/2024
1	Re-Irradiation 01/2023